𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Duloxetine in the treatment of adolescents with attention deficit/hyperactivity disorder: an open-label study

✍ Scribed by Javad Mahmoudi-Gharaei; Nasrin Dodangi; Mehdi Tehrani-Doost; Toktam Faghihi

Publisher
John Wiley and Sons
Year
2011
Tongue
English
Weight
90 KB
Volume
26
Category
Article
ISSN
0885-6222

No coin nor oath required. For personal study only.

✦ Synopsis

Objective The main aim of this study was to explore the efficacy and safety of duloxetine, a serotonin and norepinephrine reuptake inhibitor, in the treatment of adolescents with attention deficit/hyperactivity disorder (ADHD). Methods Seventeen adolescents aged 11-18 years, diagnosed with ADHD, participated in this 6-week open-label study. Duloxetine was given in doses of 30 mg/day in the first week and 60 mg/day from week 2 to the end of the study. Conners' Parent Rating Scale-Revised (CPRS-R) short form was used to assess the efficacy of the therapy. Results A significant reduction in ADHD symptoms measured by CPRS-R was observed. This reduction was evident from week 4 of the study. In addition, the decrease was significant in all four subscales of CPRS-R including inattention, oppositionality, hyperactivity and ADHD index. In terms of side effects, duloxetine was generally safe and well tolerated. Conclusions The results of this open-label study suggest a promise of duloxetine in the treatment of youth with ADHD. Further controlled studies with larger samples are required to evaluate the efficacy of duloxetine in children and adolescents with ADHD.

πŸ“œ SIMILAR VOLUMES

An open trial of buspirone in the treatm
An open trial of buspirone in the treatment of attention-deficit disorder
✍ Helmut Niederhofer πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 48 KB

## Abstract ## Objective Medications such as clonidine have been shown to facilitate calming, to enhance frustration tolerance, and to reduce aggression in attention deficit disorder (ADD) patients. The use of buspirone was studied as an alternative because of its longer excretion half‐life, decre

Duloxetine in the treatment of irritable
Duloxetine in the treatment of irritable bowel syndrome: an open-label pilot study
✍ Brian P. Brennan; Kate V. Fogarty; Jacqueline L. Roberts; Karina A. Reynolds; Ha πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 94 KB πŸ‘ 2 views

## Abstract ## Objective To assess the efficacy of duloxetine for irritable bowel syndrome (IBS). ## Methods We conducted an open‐label 12‐week trial of duloxetine 60 mg daily in 15 patients with IBS without concurrent major depressive disorder. The primary outcome measure was average abdominal

The efficacy of reboxetine in the treatm
The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study
✍ P. N. Dannon; I. Iancu; L. Grunhaus πŸ“‚ Article πŸ“… 2002 πŸ› John Wiley and Sons 🌐 English βš– 57 KB πŸ‘ 2 views

## Abstract ## Background and Objective Selective serotonin reuptake inhibitors (SSRIs) are currently the first‐line treatment for panic disorder, although up to 30% of patients either do not respond to SSRIs or withdraw due to adverse events. Reboxetine, a selective norepinephrine reuptake inhibi